Microbot Medical Valuation
Is CY9D undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CY9D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CY9D's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CY9D's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CY9D?
Key metric: As CY9D is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is CY9D's PB Ratio? | |
|---|---|
| PB Ratio | 4.4x |
| Book | US$3.81m |
| Market Cap | US$16.59m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1.2x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does CY9D's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.7x | ||
GME Geratherm Medical | 0.7x | 89.5% | €15.0m |
NN6 NanoRepro | 0.5x | n/a | €19.6m |
AAQ1 aap Implantate | 1.6x | n/a | €22.4m |
AUG Audientes | 3.9x | n/a | €6.9m |
CY9D Microbot Medical | 4.4x | n/a | €16.6m |
Price-To-Book vs Peers: CY9D is expensive based on its Price-To-Book Ratio (4.4x) compared to the peer average (0.9x).
Price to Book Ratio vs Industry
How does CY9D's PB Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Book vs Industry: CY9D is expensive based on its Price-To-Book Ratio (4.4x) compared to the European Medical Equipment industry average (2.1x).
Price to Book Ratio vs Fair Ratio
What is CY9D's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 4.4x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate CY9D's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
Top Glove Corporation Bhd
RM 7.8b
An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.
5OU
RM 0.98
7D
0.5%
1Y
-82.5%